A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The main objectives of this phase 1 trial are to evaluate the effect of food on the
pharmacokinetics (i.e. how long and how much a compound is present in the blood) of
ACT-541468 and to evaluate whether ACT-541468 can affect the pharmacokinetics of midazolam, a
CYP3A4 substrate.